XiJia Medical Unveils Precision Neuronavigation TMS System in Artery Product Launch Series Episode 127

In recent years, there has been a large number of patients with neurological disorders and psychiatric conditions such as Alzheimer's disease and depression. Currently, many of these conditions lack effective pharmacological treatments, and certain medications may cause side effects such as addiction. As a mature device with over thirty years of clinical application, transcranial magnetic stimulation (TMS) is supported by extensive clinical cases and research demonstrating its efficacy.

TMS (Transcranial Magnetic Stimulation) is a mature and widely adopted therapeutic modality, approved for the treatment of depression since 2008. It has been extensively studied internationally, covering a broad spectrum of conditions with high-level evidence, and is recognized as one of the four major brain science technologies of the 21st century. By stimulating specific brain regions, TMS can inhibit or enhance various brain functions. Its mechanism of action involves reconfiguring neural circuits and restoring normative inter-regional communication within the brain.

The limitation of traditional TMS lies in the lack of specific targets, resulting in limited efficacy due to the inability to deliver precise treatment. NuraNavX has achieved a breakthrough by leveraging personalized connectomic brain mapping technology to identify abnormal neural targets in patients’ brains, thereby enabling neuronavigation-guided precise TMS therapy and significantly improving clinical response rates.

NuraNavX Precision TMS Treatment Process:

NuraNavX Precision TMS Treatment Efficacy:

The overall treatment efficacy rate exceeds 80% for various conditions, including depression, anxiety disorders, sleep disorders, stroke rehabilitation, post-oncological surgical rehabilitation, dementia, and schizophrenia.

NuraNavX Medical Product Collaboration Model:

● NuraNavX’s neurosurgical products are primarily marketed through in-hospital sales, supplemented by out-of-hospital channels;

● Precision TMS products are primarily offered through outpatient clinics, with distributors facilitating connections to clinic partners or direct customer acquisition.

● For clinic partners, NuraNavX’s TMS products are primarily offered through two collaboration models. Under the co-construction model, the partner provides the facility and necessary qualifications, while NuraNavX supplies the equipment and handles operations, with revenue shared between both parties. Under the technology licensing model, NuraNavX directly provides target analysis services to partner clinics, charging on a per-case basis.

Zhang Xia

NuraNavX | Medical Director

Ph.D. from Nanjing Medical University, Postdoctoral Fellow at Peking University Third Hospital, Associate Chief Physician. Possesses extensive experience in neuroscience, rehabilitation medicine, management, and scientific research. Has presided over or participated in 15 research projects, with a total funding of 20 million RMB. Serves as Deputy Secretary-General of the Chinese Association of Rehabilitation Medicine, Member of the 9th National Committee of the China Association for Science and Technology, and Member of the Society of Physical Medicine and Rehabilitation. Acts as a reviewer for domestic and international journals in rehabilitation medicine and related fields. Previously served as Assistant to the President of Xidian Group Hospital and Technical Director of General Global Medical Group.

Yuanquan

NuraNavX | Head of Operations

Holds a Master of Professional Accounting from Fudan University, with over 10 years of experience in capital market investment and research. Previously served at institutions such as Changfeng Huixin Equity, Lead Capital, and UG Investment, holding positions including Investment Director, Research Director, and Member of the Investment Decision Committee. Possesses extensive industry research experience and a profound understanding of corporate business development and the value of cutting-edge technologies. Currently responsible for market expansion and operations of NuraNavX’s brain atlas products.

NuraNavX is a global innovation leader in the fields of connectomics and personalized brain mapping, co-founded by top international experts in medicine and artificial intelligence. As the first medical technology company to achieve FDA clearance for a connectomics-based product, we integrate MRI imaging technology, brain connectomics, and machine learning algorithms to pioneeringly construct the world’s first scalable personalized brain mapping system. This advancement ushers in an era of personalized and precision brain healthcare, delivering accurate diagnosis and treatment to safeguard patients’ brain health.

We currently offer two products: QuicktomeTM 1.x, which assists neurosurgeons in preoperative planning by visualizing brain networks through MRI data processing, thereby avoiding damage to critical functional networks during surgery and improving patients' postoperative quality of life. QuicktomeTM 2.x provides personalized, precise assessment and targeted treatment for conditions managed by neurology, rehabilitation, and psychiatry departments—including postoperative rehabilitation, depression, anxiety, insomnia, stroke, and dementia—ushering in a new era of neuromodulation.

“Artery New Product Showcase” is a live-streaming program designed to support medical enterprises in launching their innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product. If your company plans to release an innovative medical product or achieve a significant milestone and wishes to participate in the “Artery New Product Showcase,” please add our assistant for consultation.

Scan the QR code below to contact the assistant for live stream reservation (if already added, please proactively reach out to the assistant)

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight].